CBIO vs SLBT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CBIO · Crescent Biopharma$13.54 ▲ 4.64%
SLBT · SL Science$0.94 ▲ 4.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CBIO +3.3%
- SLBT -91.0%
Head to head
| Metric | CBIO | SLBT |
|---|---|---|
| Price | $13.54 | $0.94 |
| Change today | ▲ 4.64% | ▲ 4.16% |
| Market cap | $502.93M | $525.71M |
| Return, 3 months | -21.9% | -66.9% |
| Return, year to date | +14.2% | -91.1% |
| Return, 1 year | +3.1% | -91.0% |
| P/E (TTM) | -96.7 | -85.2 |
| P/B | 3.2 | 78.1 |
| P/E percentile vs own 5y | 5th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -34.7% |
| Net profit growth (YoY) | -14.0% | -220.6% |
| Gross margin | – | 38.4% |
| Operating margin | -1,417.7% | -178.8% |
| Net margin | -1,389.6% | -178.4% |
| Return on equity | -112.1% | -74.9% |
| Analyst target vs. price | +134.5% | – |
| Analyst buy share | 100% | – |
| RSI (14) | 49 | 26 |
| 30-day volatility | 65.1% | 111.7% |
| Max drawdown, 1 year | -56.1% | -93.0% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLBT is the largest of the group by market value.
- CBIO has returned the most over the past year.
- CBIO carries the lowest trailing P/E.
- SLBT keeps the most profit per dollar of sales.
- CBIO has been the calmest stock over the last 30 days.